



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

Date: May 26, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,

**Subject: Press Release- Appointment of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D designated as Key Managerial Personnel of the Company**

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release for Appointment of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D designated as Key Managerial Personnel of the Company w.e.f. May 26, 2023.

Request you to kindly take the same on record.

Thanking you,

**For Supriya Lifescience Limited**

**Shweta Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A44973**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.–Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



## SUPRIYA LIFESCIENCE LTD.

### Supriya Lifescience Limited announces appointment of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

**Investor Release (26<sup>th</sup> May 2023): Supriya Lifescience Ltd.** a cGMP compliant company having a well established presence in API Manufacturing with focus in products of various therapeutic segments like - Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti-Asthmatics etc. has announced appointment of Dr. Shekhar Bhirud as President - Business Development, Strategy and R&D.

Dr. Shekhar Bhirud has over 34+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Business development of API's, API R&D function with strategic planning to convert the unit into profit centeric mindset.

Dr Bhirud is a Ph.D (Chem) holder from Mumbai University, Maharashtra in 1988. He also holds M.Sc (Chem) & B.Sc (Chem) with first class.

Dr. Bhirud played a vital role in process development, optimization, and commissioning of the various plants across multiple companies. His close collaboration with international scientists and his responsibility for standardizing production and quality control earned him recognition at workplaces.

During his long span of career he has consistently displayed a passion for innovation and has made significant contributions to the field. With an impressive record of 73 process patents and several scientific publications to his credit, he has showcased his ability to drive research and development initiatives.

Throughout his career, he has maintained an impeccable record with reputable companies like Cipla Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd., DAI-ICHI Karkaria Ltd, Akums Drugs & Pharmaceutical Ltd Ind Swift Labs, Farmaprojects S.A, Glaxo Ltd, Etc.

He has strategic leadership attributes with a strong business acumen and a track record of delivering exceptional results. His extensive experience in diverse areas of the pharmaceutical industry, combined with his strategic thinking and innovation-driven mindset, make him a valuable asset to any organization.

*Commenting on the appointment, **Dr. Satish Wagh**, Chairman & Managing Director, stated "Mr. Bhirud's exceptional expertise and extensive experience in the pharmaceutical industry, we are confident that he is the perfect leader for our organization. His remarkable background in the pharma sector, coupled with his hands-on approach, will greatly contribute to strengthening our manufacturing excellence and driving strategic alliances."*

***Dr. Shekhar Bhirud**, stated "I am thrilled to become a part of the dynamic Supriya team. Supriya's exceptional business model and talented management team create a unique advantage for us to seize opportunities in the evolving pharmaceutical landscape. I firmly believe that Supriya is well-positioned to achieve new milestones through strategic initiatives."*



## SUPRIYA LIFESCIENCE LTD.

### **About Supriya Lifescience Limited**

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience is today. Company is leader in Therapeutic Segments like Anti-Histamines, Anti-Allergics, Anti-Asthmatics, Anesthetics & Vitamins. SupriyaLifescience has State-of-the-art manufacturing facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. Facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

### **Safe Harbor**

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

---

#### **Company:**

#### **Investor Relations Advisors:**



**SUPRIYA LIFESCIENCE LTD.**

**Supriya Lifescience Limited**

CIN: L51900MH2008PLC180452

**Mr. Krishna Raghunathan**

Chief Financial Officer

[cfo@supriyalifescience.com](mailto:cfo@supriyalifescience.com)



**orient capital**

**Orient Capital** (a division of Link Group)

**Mr. Rajesh Agrawal**

+91 99674 91495

[rajesh.agrawal@linkintime.co.in](mailto:rajesh.agrawal@linkintime.co.in)

---